Revenue Update on InVitae Corp(NYSE:NVTA)

InVitae Corp(NYSE:NVTA) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 13, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $9.236M. Analysts estimated a revenue of $8.820M. The revenues were 4.72% above the estimates. Earnings per share were $-0.69. The reported EPS was above estimates by 6.76%. Analysts had estimated an EPS of $-0.74.

InVitae Corp (NVTA) shares turned negative on Wednesdays trading session with the shares closing down -0.12 points or -1.17% at a volume of 3,12,784. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $10.44. The peak price level was also seen at $10.44 while the days lowest was $10.06. Finally the shares closed at $10.11. The 52-week high of the shares is $11.85 while the 52-week low is $5.76. According to the latest information available, the market cap of the company is $416 M.

Several Insider Transactions has been reported to the SEC. On Nov 22, 2016, Randal W Scott (CEO) purchased 66,666 shares at $6.00 per share price.Also, On Nov 21, 2016, Geoffrey Crouse (director) purchased 15,000 shares at $6.25 per share price.On Nov 21, 2016, Eric Aguiar (director) purchased 10,000 shares at $6.28 per share price, according to the Form-4 filing with the securities and exchange commission.

Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The Company has two laboratories: one in San Francisco California and a second in Santiago Chile. The Company’s first product is an assay of 216 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer neurological disorders cardiovascular disorders and other hereditary conditions. The Company also offers panels for pediatric conditions such as Noonan spectrum disorders and ciliopathies.

Add Comment